Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 18/20 | 1.00 |
| ▸ | CNR1 | P21554 | 6/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sr-144528 SCHEMBL1546003 | 1.00 | CNR2 (1.00) | CNR2CNR1 | |
| Sr-144528 SCHEMBL14355050 | 1.00 | CNR2 (1.00) | CNR2CNR1 | |
| Sr-144528 SCHEMBL8039660 | 1.00 | CNR2 (1.00) | CNR2CNR1 | |
| Sr-144528 SCHEMBL8313006 | 1.00 | CNR2 (1.00) | CNR2CNR1 | |
| Sr-144528 SCHEMBL19551517 | 1.00 | CNR2 (1.00) | CNR2CNR1 | |
| Sr-144528 SCHEMBL1432281 | 1.00 | CNR2 (1.00) | CNR2CNR1 | |
| SCHEMBL13883212 | 0.94 | CNR2 (0.88) | CNR2CNR1 | |
| SCHEMBL13926164 | 0.94 | CNR2 (0.88) | CNR2CNR1 | |
| SCHEMBL15377558 | 0.92 | CNR2 (0.85) | CNR2CNR1 | |
| SCHEMBL8042546 | 0.92 | CNR2 (0.85) | CNR2CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4146345-A2 | CANNABINOID RECEPTOR TYPE 2 (CB2) MODULATORS AND USES THEREOF | Teon Therapeutics, Inc. (US) | 2023-03-15 | — | — | EP | claimed |
| WO-2021226206-A2 | CANNABINOID RECEPTOR TYPE 2 (CB2) MODULATORS AND USES THEREOF | TEON THERAPEUTICS, INC. (US) | 2021-11-11 | — | — | WO | claimed |
| US-20200289458-A1 | TOPICAL FORMULATIONS OF CANNABINOIDS AND USE THEREOF IN THE TREATMENT OF PAIN | INMED PHARMACEUTICALS INC (CA) | 2020-09-17 | — | — | US | claimed |
| EP-3558281-A1 | TREATMENT OF MENTAL, MOVEMENT AND BEHAVIORAL DISORDERS | Anavi-Goffer, Sharon (IL) | 2019-10-30 | — | — | EP | claimed |
| US-20190321355-A1 | TREATMENT OF MENTAL, MOVEMENT AND BEHAVIORAL DISORDERS | ANAVI GOFFER SHARON (IL) | 2019-10-24 | — | — | US | claimed |
| US-20190142788-A1 | USE OF TOPICAL FORMULATIONS OF CANNABINOIDS IN THE TREATMENT OF EPIDERMOLYSIS BULLOSA AND RELATED CONNECTIVE TISSUE DISORDERS | INMED PHARMACEUTICALS INC. (CA) | 2019-05-16 | — | — | US | claimed |
| EP-3452036-A1 | USE OF TOPICAL FORMULATIONS OF CANNABINOIDS IN THE TREATMENT OF EPIDERMOLYSIS BULLOSA AND RELATED CONNECTIVE TISSUE DISORDERS | Inmed Pharmaceuticals Inc. (CA) | 2019-03-13 | — | — | EP | claimed |
| US-20190008845-A1 | PROGRAM RANDOMIZATION FOR CYBER-ATTACK RESILIENT CONTROL IN PROGRAMMABLE LOGIC CONTROLLERS | SIEMENS AKTIENGESELLSCHAFT (DE) | 2019-01-10 | — | — | US | claimed |
| WO-2018112138-A1 | TREATMENT OF MENTAL, MOVEMENT AND BEHAVIORAL DISORDERS | ANAVI GOFFER SHARON (IL) | 2018-06-21 | — | — | WO | claimed |
| WO-2017190249-A1 | USE OF TOPICAL FORMULATIONS OF CANNABINOIDS IN THE TREATMENT OF EPIDERMOLYSIS BULLOSA AND RELATED CONNECTIVE TISSUE DISORDERS | INMED PHARMACEUTICALS INC. (CA) | 2017-11-09 | — | — | WO | claimed |
| EP-4727648-A1 | CANNABINOID RECEPTOR 2 MODULATORS | F. Hoffmann-La Roche AG (CH) | 2026-04-22 | — | — | EP | disclosed |
| US-20250332180-A1 | CANNABINOIDS AND IL-15 ACTIVATE NK CELLS | UNIV CALIFORNIA (US) | 2025-10-30 | — | — | US | disclosed |
| US-12357604-B2 | Topical formulations of cannabinoids and use thereof in the treatment of pain | INMED PHARMACEUTICALS INC. (CA) | 2025-07-15 | — | — | US | disclosed |
| WO-2025090587-A1 | CANNABINOIDS COMPOUNDS AND THEIR USE IN THE TREATMENT OF NEURONAL DISORDERS | INMED PHARMACEUTICALS INC. (CA) | 2025-05-01 | — | — | WO | disclosed |
| WO-2025090133-A1 | COMPOSITIONS AND METHODS FOR USE OF CANNABINOL COMPOUNDS IN NEUROPROTECTION | INMED PHARMACEUTICALS INC. (CA) | 2025-05-01 | — | — | WO | disclosed |
| US-7763607-B2 | Pharmaceutical compositions comprising CBx cannabinoid receptor modulators and potassium channel modulators | SOLVAY PHARMACEUTICALS GMBH (DE) | 2010-07-27 | — | — | US | disclosed |
| US-7763607-B2 | Pharmaceutical compositions comprising CBx cannabinoid receptor modulators and potassium channel modulators | SOLVAY PHARMACEUTICALS GMBH (DE) | 2010-07-27 | — | — | US | disclosed |
| WO-2007125048-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING CBX CANNABINOID RECEPTOR MODULATORS AND POTASSIUM CHANNEL MODULATORS | SOLVAY PHARMACEUTICALS GMBH (DE) | 2007-11-08 | — | — | WO | disclosed |
| US-20070254862-A1 | Pharmaceutical compositions comprising CBx cannabinoid receptor modulators and potassium channel modulators | SOLVAY PHARMACEUTICALS GMBH (DE) | 2007-11-01 | — | — | US | disclosed |
| US-20070254862-A1 | Pharmaceutical compositions comprising CBx cannabinoid receptor modulators and potassium channel modulators | SOLVAY PHARMACEUTICALS GMBH (DE) | 2007-11-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190321355-A1 | TREATMENT OF MENTAL, MOVEMENT AND BEHAVIORAL DISORDERS | HTR2C, CNR1, HTR4 | CNR2 4/4885CNR1 2/4885 |
| US-12357604-B2 | Topical formulations of cannabinoids and use thereof in the treatment of pain | CNR2, CNR1, LCAT | CNR2 1/4885CNR1 2/4885 |
| US-20200289458-A1 | TOPICAL FORMULATIONS OF CANNABINOIDS AND USE THEREOF IN THE TREATMENT OF PAIN | CNR2, CNR1, LCAT | CNR2 1/4885CNR1 2/4885 |
| US-20070254862-A1 | Pharmaceutical compositions comprising CBx cannabinoid receptor modulators and potassium channel modulators | CNR1, CNR2, KCNJ11 | CNR2 2/4885CNR1 1/4885 |
| US-20190008845-A1 | PROGRAM RANDOMIZATION FOR CYBER-ATTACK RESILIENT CONTROL IN PROGRAMMABLE LOGIC CONTROLLERS | CNR1, CNR2, HTR4 | CNR2 2/4885CNR1 1/4885 |
| US-20190142788-A1 | USE OF TOPICAL FORMULATIONS OF CANNABINOIDS IN THE TREATMENT OF EPIDERMOLYSIS BULLOSA AND RELATED CONNECTIVE TISSUE DISORDERS | KRT18, DSP, DSC1 | CNR2 28/4885CNR1 60/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.